Cholangiocarcinoma Market Size was USD 786.1 Million in 2021

"The increase in Cholangiocarcinoma market size is a direct consequence of increasing incident population of Cholangiocarcinoma, an increase in investment in the R&D of drugs leading to a rich pipeline in the 7MM"

The Cholangiocarcinoma market report provides current treatment practices, emerging drugs, cholangiocarcinoma market share of the individual therapies, current and forecasted cholangiocarcinoma market Size from 2019 to 2032 segmented by seven major markets. The Report also covers current cholangiocarcinoma treatment practice/algorithm, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

Key takeaways from the Cholangiocarcinoma Market Report

• In 2021, the total Cholangiocarcinoma market size was USD 786.1 million which is expected to rise during the study period (2019-2032).

• According to the DelveInsight, in the year 2021, the total diagnosed incident cases of Cholangiocarcinoma were 10,034 in the United States which are expected to grow during the study period, i.e., 2019-2032.

• The highest number of total incident cases of Cholangiocarcinoma was observed in Italy among the EU5 countries with 6,489 cases in 2021 which are expected to grow during the study period, i.e., 2019-2032.

• In the year 2021, the total diagnosed incident cases of Cholangiocarcinoma were 16,004 in Japan which are expected to grow during the study period, i.e., 2019-2032.

• The leading Cholangiocarcinoma Market Companies include AstraZeneca, Decalth Systems, Basilea Pharmaceutical, Taiho Oncology, Eisai Pharmaceuticals, TransThera Sciences, Incyte Corporation, Roche, Agios Pharmaceuticals, Servier Pharmaceuticals, and others.

• Promising Cholangiocarcinoma Pipeline Therapies include BGJ398 (infigratinib), Gemcitabine, Cisplatin, CX-4945, E7090, Pemigatinib, Derazantinib, TAS-120, and others.

For more insights into the Cholangiocarcinoma Market Landscape, visit Cholangiocarcinoma Market Therapeutics Landscape @ https://www.delveinsight.com/sample-request/cholangiocarcinoma-cca-market-insights-epidemiology-and-market-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Recent Developmental Activities in the Cholangiocarcinoma Treatment Landscape

• KEYTRUDA (pembrolizumab) is being developed by Merck is an anti-PD-1 therapy that works by increasing the ability of the body's immune system to help detect and fight tumor cells. It is a humanized monoclonal antibody that blocks the interaction between PD-1 and its ligands, PD-L1, and PD-L2, thereby activating T lymphocytes which may affect both tumor cells and healthy cells. Currently, Keytruda is being evaluated in Phase III (NCT04003636. KEYNOTE-966) clinical trial. This is a study of the combination of pembrolizumab plus gemcitabine/cisplatin versus placebo plus gemcitabine/cisplatin as first-line therapy in participants with advanced and/or unresectable biliary tract carcinoma. The study is anticipated to complete by November 2024.

• Currently, Zymeworks and BeiGene are co-developing Zanidatamab which is a bispecific antibody that can simultaneously bind two non-overlapping epitopes, known as biparatopic binding, of HER2, resulting in dual HER2 signal blockade, increased binding and removal of HER2 protein from the cell surface, and potent effector function mediated cytotoxicity, enhanced antibody internalization and HER2 downregulation and enhanced blockade of ligand-dependent and ligand-independent tumor growth. Zanidatamab is being evaluated in global Phase II (NCT03929666). The study is anticipated to be complete by April 2024.

• Eisai is currently developing its lead product candidate Tasugratinib (E7090) which is discovered in-house by Eisai's Tsukuba Research Laboratories, E7090 is an orally available novel tyrosine kinase inhibitor that demonstrates selective inhibitory activity against fibroblast growth factor receptors (FGFR) FGFR1, FGFR2 and FGFR3. It has been granted the orphan drug designation with a prospective indication for unresectable biliary tract cancer with FGFR2 gene fusion by the Ministry of Health, Labour and Welfare (MHLW) in Japan. Currently, a Phase II (NCT04238715) clinical trial of E7090 is underway in Japan and China to evaluate efficacy and safety in patients with cholangiocarcinoma with FGFR2 gene fusion. The study is anticipated to be complete by September 2023.

Cholangiocarcinoma Epidemiology Segmentation in the 7MM

• Total Cholangiocarcinoma Diagnosed-incidence Cases
• Total Cholangiocarcinoma Type-specific Cases
• Total Cholangiocarcinoma Age-specific Cases
• Total Cholangiocarcinoma Stage-specific Cases
• Total Cholangiocarcinoma Mutation-specific Cases
• Total Cholangiocarcinoma Treated Cases (across lines)

To know more information of the Cholangiocarcinoma Epidemiology Segmentation of the report, click here for Cholangiocarcinoma Epidemiology Insights @ https://www.delveinsight.com/sample-request/cholangiocarcinoma-cca-market-insights-epidemiology-and-market-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Cholangiocarcinoma Market Insight
Photodynamic therapy can improve survival in patients with unresectable BTC. The role of radiation therapy in BTC is still not clearly outlined, but radiation with concurrent chemotherapy has been recommended in margin-positive and node-positive iCCA and pCCA, and unresectable pCCA is ineligible for liver transplantation

Cholangiocarcinoma Emerging Drugs
• LYTGOBI (futibatinib)
• TIBSOVO (ivosidenib)
• TRUSELTIQ (infigratinib)
• PEMAZYRE (pemigatinib)
• TT-00420 (TransThera Sciences, Phase II)
• KEYTRUDA (pembrolizumab) (Merck Sharp & Dohme, Phase III)

Browse More Related Reports of the Cholangiocarcinoma Market Research Reports, click here for Cholangiocarcinoma Market Forecast @ https://www.delveinsight.com/sample-request/cholangiocarcinoma-cca-market-insights-epidemiology-and-market-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Cholangiocarcinoma Market Report

• Coverage- 7MM

• Cholangiocarcinoma Companies- AstraZeneca, Decalth Systems, Basilea Pharmaceutical, Taiho Oncology, Eisai Pharmaceuticals, TransThera Sciences, Incyte Corporation, Roche, Agios Pharmaceuticals, Servier Pharmaceuticals, and others.

• Cholangiocarcinoma Pipeline Therapies- BGJ398 (infigratinib), Gemcitabine, Cisplatin, CX-4945, E7090, Pemigatinib, Derazantinib, TAS-120, and others.

• Cholangiocarcinoma Market Dynamics: Cholangiocarcinoma Market Drivers and Barriers

• Cholangiocarcinoma Market Access and Reimbursement, Unmet Needs, Future Perspectives

Read the Full Research Report of the Cholangiocarcinoma Market Forecast Report, click here for Cholangiocarcinoma Market Drivers and Barriers @ https://www.delveinsight.com/sample-request/cholangiocarcinoma-cca-market-insights-epidemiology-and-market-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Key Insights
2. Executive Summary of Cholangiocarcinoma (CCA)
3. Cholangiocarcinoma (CCA) Market Overview at a Glance
4. Cholangiocarcinoma (CCA): Disease Background and Overview
5. Treatment
6. Epidemiology and Patient Population
7. United States Epidemiology
8. EU5 Epidemiology
9. Japan Epidemiology
10. Patient Journey
11. Key endpoints in Cholangiocarcinoma trials
12. Marketed Cholangiocarcinoma Drugs
13. Emerging Cholangiocarcinoma Therapies
14. Conjoint Analysis
15. Cholangiocarcinoma (CCA): 7MM Market Analysis
16. Cholangiocarcinoma Market Access and Reimbursement
17. KOL views
18. Cholangiocarcinoma Market Drivers
19. Cholangiocarcinoma Market Barriers
20. SWOT Analysis
21. Cholangiocarcinoma Unmet needs
22. Appendix
23. DelveInsight Capabilities
24. Disclaimer
25. About DelveInsight

Consult with our Business Expert @ Cholangiocarcinoma Market Landscape- https://www.delveinsight.com/sample-request/cholangiocarcinoma-cca-market-insights-epidemiology-and-market-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Contact Us

Yash Bhardwaj

info@delveinsight.com

This release was published on openPR.